PI3K: A Crucial Piece in the RAS Signaling Puzzle

被引:48
作者
Krygowska, Agata Adelajda [1 ]
Castellano, Esther [1 ]
机构
[1] Queen Mary Univ London, Ctr Canc & Inflammat, Barts Canc Inst, London EC13 6BQ, England
来源
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE | 2018年 / 8卷 / 06期
关键词
PHOSPHOINOSITIDE 3-KINASE P110-ALPHA; EXTRACELLULAR-MATRIX SYNTHESIS; MUTANT COLORECTAL CANCERS; CELL LUNG-CANCER; G-BETA-GAMMA; PHOSPHATIDYLINOSITOL; 3-KINASE; K-RAS; ANTITUMOR-ACTIVITY; ONCOGENIC RAS; CROSS-TALK;
D O I
10.1101/cshperspect.a031450
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
RAS proteins are key signaling switches essential for control of proliferation, differentiation, and survival of eukaryotic cells. RAS proteins are mutated in 30% of human cancers. In addition, mutations in upstream or downstream signaling components also contribute to oncogenic activation of the pathway. RAS proteins exert their functions through activation of several signaling pathways and dissecting the contributions of these effectors in normal cells and in cancer is an ongoing challenge. In this review, we summarize our current knowledge about how RAS regulates type I phosphatidylinositol 3-kinase (PI3K), one of the main RAS effectors. RAS signaling through PI3K is necessary for normal lymphatic vasculature development and for RAS-induced transformation in vitro and in vivo, especially in lung cancer, where it is essential for tumor initiation and necessary for tumor maintenance.
引用
收藏
页数:19
相关论文
共 201 条
  • [1] Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance
    Aksamitiene, Edita
    Kiyatkin, Anatoly
    Kholodenko, Boris N.
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 139 - 146
  • [2] Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
    Alagesan, Brinda
    Contino, Gianmarco
    Guimaraes, Alexander R.
    Corcoran, Ryan B.
    Deshpande, Vikram
    Wojtkiewicz, Gregory R.
    Hezel, Aram F.
    Wong, Kwok-Kin
    Loda, Massimo
    Weissleder, Ralph
    Benes, Cyril
    Engelman, Jeffrey A.
    Bardeesy, Nabeel
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (02) : 396 - 404
  • [3] IDENTIFICATION OF THE SITES IN MAP KINASE KINASE-1 PHOSPHORYLATED BY P74(RAF-1)
    ALESSI, DR
    SAITO, Y
    CAMPBELL, DG
    COHEN, P
    SITHANANDAM, G
    RAPP, U
    ASHWORTH, A
    MARSHALL, CJ
    COWLEY, S
    [J]. EMBO JOURNAL, 1994, 13 (07) : 1610 - 1619
  • [4] K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives
    Asati, Vivek
    Mahapatra, Debarshi Kar
    Bharti, Sanjay Kumar
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 125 : 299 - 314
  • [5] A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
    Athuluri-Divakar, Sai Krishna
    Vasquez-Del Carpio, Rodrigo
    Dutta, Kaushik
    Baker, Stacey J.
    Cosenza, Stephen C.
    Basu, Indranil
    Gupta, Yogesh K.
    Reddy, M. V. Ramana
    Ueno, Lynn
    Hart, Jonathan R.
    Vogt, Peter K.
    Mulholland, David
    Guha, Chandan
    Aggarwal, Aneel K.
    Reddy, E. Premkumar
    [J]. CELL, 2016, 165 (03) : 643 - 655
  • [6] Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kγ-dependent manner
    Awad, Ahmed E.
    Kandalam, Vijay
    Chakrabarti, Subhadeep
    Wang, Xiuhua
    Penninger, Josef M.
    Davidge, Sandra T.
    Oudit, Gavin Y.
    Kassiri, Zamaneh
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2010, 298 (03): : C679 - C692
  • [7] RAS GENES
    BARBACID, M
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 : 779 - 827
  • [8] Growth arrest and autophagy are required for salivary gland cell degradation in Drosophila
    Berry, Deborah L.
    Baehrecke, Eric H.
    [J]. CELL, 2007, 131 (06) : 1137 - 1148
  • [9] KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
    Bhattacharya, Saveri
    Socinski, Mark A.
    Burns, Timothy F.
    [J]. CLINICAL AND TRANSLATIONAL MEDICINE, 2015, 4
  • [10] BOS JL, 1989, CANCER RES, V49, P4682